Back to search results

Safety of jCell (Famzeretcel) for Retinitis Pigmentosa

This study is looking at the safety of a single injection of 6.0 million jCell (famzeretcel) in adults with Retinitis Pigmentosa (RP), an eye disease that causes vision loss. Researchers want to see if this treatment is safe over six months. They will also compare changes in vision between those who receive the jCell injection and those who get a mock injection (a sham control). You might be able to join if you are between 18 and 60 years old and have a diagnosis of RP, confirmed by things like vision loss, night blindness, or specific changes in your eye scans. The study aims to enroll 60 participants.

Study design
This interventional study plans to enroll 60 participants. It compares a single injection of jCell to a mock injection (sham control) to see if the treatment is safe.
What's involved
Participants will receive either a single injection of jCell or a mock injection. Your safety and visual function will be evaluated over a six-month period.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for safety and visual function for six months after the injection.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06912633

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Active, Not Recruiting
PHASE2Ages 18–60InterventionalTreatment
jCyte, Inc
~31 participants
Updated 2026-07-30 on ClinicalTrials.gov
What's tested:human retinal progenitor cellsMock injection

At a glance

Recruiting sites
0 of 12 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety of Intravitreal Injection of 6.0M jCell
Measured over 6 months

Conditions

Retinitis Pigmentosa

Explore related trials

Retinitis Pigmentosa

NCT06912633

Where you'd take part

This study runs at 12 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Associated Retina Consultants

    Phoenix, Arizonano site contact published

  • California Retina Consultants

    Bakersfield, Californiano site contact published

  • Gavin Herbert Eye Institute, UC Irvine

    Irvine, Californiano site contact published

  • Illinois Retina Associates

    Oak Park, Illinoisno site contact published

  • Long Island Vitreoretinal Consultants

    Westbury, New Yorkno site contact published

  • NJRetina

    Teaneck, New Jerseyno site contact published

  • Retina Consultants Medical Group

    Sacramento, Californiano site contact published

  • Retina Consultants of Texas: Bellaire Retina Center

    Bellaire, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Henry Klassen, MD, PhD · PRINCIPAL_INVESTIGATOR · jCyte, Inc

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Safety of Intravitreal Injection of 6.0M jCell6 months

    Assessed by treatment emergent adverse events, immunogenicity and safety visual assessments